Joost Boeckmans Selected Research

2- (2,6- dimethyl- 4- (3- (4- (methylthio)phenyl)- 3- oxo- 1- propenyl)phenoxyl)- 2- methylpropanoic acid

1/2022	Transcriptomics Reveals Discordant Lipid Metabolism Effects between In Vitro Models Exposed to Elafibranor and Liver Samples of NAFLD Patients after Bariatric Surgery.
8/2019	Transcriptomics data of a human in vitro model of non-alcoholic steatohepatitis exposed to elafibranor.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Joost Boeckmans Research Topics

Disease

4	Alcoholic Fatty Liver 01/2022 - 01/2018
4	Fibrosis (Cirrhosis) 01/2022 - 12/2019
4	Inflammation (Inflammations) 01/2021 - 01/2018
2	Non-alcoholic Fatty Liver Disease 01/2022 - 01/2022
2	Liver Diseases (Liver Disease) 01/2021 - 01/2018
1	COVID-19 06/2021
1	Infections 01/2021
1	Fatty Liver 01/2021
1	Hepatocellular Carcinoma (Hepatoma) 01/2020

Drug/Important Bio-Agent (IBA)

4	LipidsIBA 01/2022 - 01/2020
2	2- (2,6- dimethyl- 4- (3- (4- (methylthio)phenyl)- 3- oxo- 1- propenyl)phenoxyl)- 2- methylpropanoic acidIBA 01/2022 - 08/2019
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2022
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2022
1	RNA (Ribonucleic Acid)IBA 06/2021
1	NexusIBA 01/2021
1	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 12/2019
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 12/2019
1	Pharmaceutical PreparationsIBA 12/2019
1	Triglycerides (Triacylglycerol)IBA 01/2018

Therapy/Procedure

1	Bariatric Surgery 01/2022
1	Therapeutics 01/2022